Nature Cancer：浙江大学顾臻团队等开发il-2长效缓释平台，促进癌症免疫治疗

Core Viewpoint - The article discusses the development of a long-acting IL-2 release platform using pressure-fused biomineral tablets, which enhances antitumor immune response and addresses the limitations of traditional IL-2 therapies [3][4][10]. Group 1: Long-acting Drug Delivery - Long-acting formulations can maintain drug release for weeks, months, or even years, improving patient compliance and therapeutic efficacy [2]. - Biominers like calcium carbonate (CaC) and calcium phosphate (CaP) are promising materials for constructing long-acting formulations due to their high biocompatibility and stability [2][6]. Group 2: Research Development - The research team developed a dynamic control platform for IL-2 release through the fusion of amorphous CaC and CaP under high pressure (2 GPa) [6][7]. - A hybrid biomineral with the formula Ca(CO3)x(PO4)2(1−x)/3 was created, demonstrating crystallization-driven release behavior to optimize IL-2's in vivo fate [7]. Group 3: Experimental Results - The formulation consisted of 7.5 mg of CaC nanoparticles, 2.5 mg of CaP nanoparticles, and 30 µg of IL-2, which were completely fused under pressure to form a transparent IL-2@Ca(CO3)1/2(PO4)1/3 tablet [8]. - The Ca(CO3)1/2(PO4)1/3 tablet reshaped the immunosuppressive tumor microenvironment, enhancing the distribution of IL-2 and preferentially activating cytotoxic T cells and memory T cells, leading to weeks of IL-2 retention [9]. Group 4: Antitumor Efficacy - In a melanoma model in female mice, the Ca(CO3)1/2(PO4)1/3 tablet exhibited excellent antitumor effects, inhibiting local tumor recurrence and preventing the growth of untreated distal tumors while maintaining a long-term T cell response [10].